EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2022


#166496

73pages

GlobalData

$ 3995

In Stock


EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) Epidemiology Forecast to 2022

Summary

Lung cancer is a disease of uncontrolled cell growth in the lung tissues. It is one of the most commonly occurring cancers in the world, representing almost 13% of all cancers (Ferlay et al., 2010). NSCLC is the most common type of lung cancer, comprising about 85% of all lung cancers. An estimated 1.37 million new cases of NSCLC occurred worldwide in 2008 (Ferlay et al., 2010).

This forecast was built on an in-depth analysis of historical trends for lung cancer incidence, mortality, and survival; smoking prevalence, disease stage at diagnosis, and the status of lung cancer screening programs in each market.

GlobalData epidemiologists forecast that the number of incident cases of NSCLC in the 9MM will grow from 1.03 million cases in 2012 to 1.26 million by 2022 at a rate of 2.2% per year. The increase in the number of NSCLS incident cases is driven by changes in the incidence of lung cancer, an aging population, population growth, smoking habits in men and women, and exposure to environmental risk factors. Of the nine markets, China will have the highest number of incident cases of NSCLC, growing from 0.55 million cases in 2012 to 0.69 million by 2022 at a rate of 2.5% per year. In addition to China, India and Japan are also important markets for NSCLC in the next 10 years because these countries have a growing older population, a high smoking prevalence, and few smoking bans compared with western countries.

Scope

  • The NSCLC EpiCast Report provides overview of the risk factors and the global and historical trends for NSCLC in the nine major markets (9MM): US, France, Germany, Italy, Spain, UK, Japan, China, and India. 
  • It also includes a 10-year epidemiology forecast of the diagnosed incident cases of NSCLC in these markets from 20122022. 
  • The incident cases are further segmented by sex and age (4049 years, 5059 years, 6069 years, 7079 years, and at ages 80 years and older), cancer stage at diagnosis (AJCC Stage I-IV), cancer histological subtype (adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and others), and the proportion of smokers among NSCLC cases.

Reasons to buy


  • Develop business strategies by understanding the trends shaping and driving the global NSCLC market.
  • Quantify patient populations in the global NSCLC market to improve product development, pricing, and launch plans. 
  • Organize sales and marketing efforts by identifying sex, age groups, and cancer histological subtypes that present the best opportunities for NSCLC therapeutics in each of the markets covered.